Singapore
AWAK Technologies, founded in 2007, aims to revolutionize kidney care with its sorbent technology. The company's mission is to improve the lives of dialysis patients through innovative solutions and portable dialysis systems, enhancing their quality of life.
AWAK's innovative technology addresses the challenges of kidney diseases, offering solutions for both peritoneal dialysis (PD) and hemodialysis (HD). These solutions provide freedom and mobility for patients, enabling dialysis to be performed on-the-go.
The recent $20.00M Series B investment on 13 September 2023 from Advanced Medtech, Vickers Venture Partners, Eckuity Capital, and Lion X Ventures signifies growing investor confidence in the company and its potential to disrupt the biotechnology industry.
By tackling the limitations of traditional dialysis methods and offering a patient-centric approach, AWAK Technologies is set to redefine kidney care, marking a significant advancement in the biotechnology sector.
